Gainers
Losers
Both Petrobras lines closed double digits higher, the only names in a 383-stock board to do it. MercadoLibre and Tempus AI each added more than 9%, while the worst loser gave up under 5%, so the upside skew was lopsided.
Latest Activity
BMY Coverage
10:15am ET
Investing
5 Dividend Stocks With Fortress-Like Coverage and Room for Things to Go Wrong
A fat dividend yield means nothing if the cash runs dry before the check clears. These five companies show wildly different margins of safety, and one of them barely cleared the bar…
7:15am ET
Investing
Pfizer’s Turnaround Could Be Bigger Than Investors Think, Set For 20% Upside
Ten consecutive earnings beats and a shrinking COVID hangover have Wall Street split on whether Pfizer deserves a breakout or a ceiling, and the answer hinges on a single pipeline deal that…
8:45am ET
Investing
5 High-Yield Dividends With Ex-Dates Days Away: Buy Before the Window Closes
Four dividend stocks from Philip Morris to JPMorgan Chase have ex-dates landing within days, and missing the cutoff means the payout goes to the seller. The clock is already running.
11:45am ET
Investing
Bristol Myers Squibb’s Dividend Sustainability Hinges on One Critical Cash Flow Metric
Bristol Myers Squibb has raised its dividend for 17 straight years, but a looming patent cliff on its biggest cash generator puts that streak on a collision course with reality in 2027.
Chris Lange 9:01am ET
Investing
4 Elite Dividend Stocks Yielding Up to 6.14% With Diversified Pipelines That Protect Your Payout
Patent cliffs have buried lesser pharma dividends, yet these four Big Pharma giants keep raising payouts despite losing blockbuster exclusivities worth billions. Find out which one has held its streak for 64…
11:06am ET
Investing
Pfizer’s Dividend Yield Is Enormous. But Is the Payout Still Growing?
Pfizer has raised its dividend every year for over a decade, then something changed. Before you count on that 6% yield, find out what the payout's own behavior is quietly signaling about…
3:15pm ET
Investing
How Much Do You Really Need Invested in Bristol Myers Squibb to Collect $10,000 a Year?
The exercise is simple: how large a position in Bristol Myers Squibb (NYSE:BMY | BMY Price Prediction) do you need to throw off $10,000 a year in dividend income? Start with the…
Chris Lange 11:11am ET
Investing
Here’s How Much You Need Invested to Collect $1,000 a Month in Dividends
Collecting $1,000 a month in dividends sounds simple until you realize the capital required shifts every time prices move, and choosing the wrong yield can leave you exposed to a dividend cut…
8:20am ET
Investing
Social Security’s 2027 COLA Raise Is the Biggest in 3 Years — But These 5 Dividend Stocks Pay You More
Social Security's projected 2027 COLA raise sounds promising until you realize retirees feel higher prices months before benefits catch up. Five blue-chip dividend stocks already pay yields that outpace that adjustment, and…
1:00pm ET
Investing
Forget the Dividend. This Could Be the Real Reason to Buy Pfizer Stock Now
Pfizer's 5.91% yield draws most of the headlines, but a quietly rerated stock and a pipeline loaded with 2026 catalysts are building a separate case altogether for investors willing to look past…
2:02pm ET
Investing
This Popular Healthcare ETF Is Diluting Your Dividend Income
XLV bundles the entire healthcare sector into one tidy package, but its cap-weighted structure quietly siphons off the income that dividend investors came for. Three stocks already inside the fund tell a…
11:00am ET
Investing
Pfizer Stock: Wall Street Sees a Rebound, Here’s Our Price Target
Pfizer shares sit near a 52-week high after years of post-pandemic punishment, and now Wall Street analysts are quietly shifting their tone. Here is what the pipeline, the dividend, and the valuation…
8:20am ET
Investing
JP Morgan Warns of Fall Sell-Off Potential: 5 Defensive Dividend Stocks to Buy
J.P. Morgan's technical team sees deteriorating market internals and a pattern eerily similar to the months before the 1999 tech crash. Five dividend-paying stocks across defensive sectors may offer shelter if the…
10:40am ET
Investing
Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPO
Seaport Therapeutics just went public with a prodrug platform that has attracted board members from two of the biggest neuroscience acquisitions in recent history. The question is whether the same giants who…
8:10am ET
Investing
Why Novartis, Lilly, and Bristol Myers Are Eyeing This Clinical-Stage Cancer Play
A clinical-stage radiopharmaceutical startup with no product revenue just caught the attention of three of pharma's biggest acquirers, and the rights structure hiding inside its Lilly partnership may explain exactly why.